Garnier 69364 Lyon cedex 7; thierry.baron@anses.fr; Tel: +33 (0)4 78 69 68 33; Fax: +33 1 5 (0)4 78 61 91 45 1 6 1 7 Abstract word count: 199 1 8 Main text word count: 3885 1 9 2 0 2 1 2 ABSTRACT 2 2 Parkinson's disease (PD) and multiple system atrophy (MSA) are neurodegenerative diseases 2 3 Introduction 3 9 Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system 4 0 atrophy (MSA) are synucleinopathies, characterized by inclusions mainly composed of an 4 1 aggregated form of α -synuclein (α-syn) in the central nervous system (CNS). As for prions, 4 2 aggregated forms of α -syn propagate within the CNS during the associated neuro-4 3 degenerative diseases. This characteristic was initially suggested in humans by Braak's 4 4 description of PD stages, and was confirmed later in experimental models of 4 5 synucleinopathies, in particular in the M83 transgenic mouse model 1 . M83 mice express the 4 6 human A53T mutated α -syn found in some familial PD forms, under the control of the mouse 4 7 prion promoter 1 . These mice spontaneously develop severe motor impairment at 8-16 months 4 8 of age at the homozygous state. The symptomatology is associated with the accumulation in 4 9 7 9 8 5 (AAVGFP) gene under the control of the human synapsin1 promoter and with a post-8 6 transcriptional WPRE regulatory sequence (Supplementary figure 1A). 8 7 5
Here, in order to assess the effects of β -syn overexpression in the context of these recent and 7 0
unexpected data suggesting that β-syn produced using AAV may be able to aggregate, we indicate that, regardless of the AAV inoculation strategy, continuous AAV-mediated β -syn 7 8 overexpression in neurons did not delay the onset of the disease and did not modify the α -syn P levels measured by ELISA, strongly suggesting that β -syn may not protect against α -syn 8 0 aggregation and propagation. In both experiments, no delay in the onset of the disease was observed in AAVβ-syn injected 1 0 3 mice as compared to control AAVGFP mice, regardless of the type of inoculum (M83/M83 or 1 0 4 MSA/M83). Instead, AAVβ-syn injection significantly accelerated the onset of the disease in 1 0 5 animals challenged with the M83/M83 extract as compared to control mice (log rank test 1 0 6 p<0,05) ( Figure 1B) . In contrast, no difference was observed in animals challenged with the 1 0 7
MSA/M83 extract ( Figure 1E ). After dissection of the brains, biochemical analyses were 1 0 8
realized. As the vector expression was higher in the rostral regions of the brain than in other 1 0 9
CNS regions after ICV injections, we first checked the vector expression by detecting total β - We next examined the possible effects of AAVβ-syn ICV injection on the spontaneous 1 3 9 development of the M83 disease during aging, without any challenge to accelerate the disease 1 4 0 ( Figure 3A) . Here again, AAVβ-syn injection neither delayed the disease onset of M83 mice 1 4 1 nor modified the α -syn P levels ( Figure 3B and D) , despite a sustained expression of the 1 4 2 transgene, at least in the hippocampus, up to the disease onset ( Figure 3C ) (ELISA data 1 4 3 correspond to 2 mice for the treated group and 3 mice for the control group; consequently, no 1 4 4 statistical analysis was done here). Altogether, these results indicated that AAVβ-syn injection in the ventricles resulted in a 1 4 6 widespread expression of the transgene in the CNS, but at a moderate level, especially in the 1 4 7
structures that are the most heavily affected by the synucleinopathy lesions. We thus 1 4 8 considered another strategy by inoculating the AAV vectors in the ventral tegmental area 1 4 9
(VTA), which is located into the mesencephalon, where major brain lesions and accumulation 1 5 0 of α -syn P are detected in sick M83 mice and which is also connected to multiple brain areas 1 5 1 13 . In order to validate this injection protocol of AAV vectors into the VTA, two months old 1 5 4
wild-type mice were first inoculated with AAVβ-syn in the VTA and sacrificed one month results raise the possibility that β -syn might be able to accelerate the aggregation of α -syn in 2 9 0 M83 mice, although this has not been reported so far. Further analyzing the effects of β -syn expression in sick M83 mice inoculated with the AAV 2 9 2 vector in the VTA allowed detecting a punctate pattern of β-syn staining in the targeted brain was more resistant to PK digestion than that endogenous β -syn in control mice. This result 2 9 5
suggests that overexpressed β -syn formed aggregates which could explain why β -syn did not staining of β -syn resistant to PK digestion referred as "dark punctae", two months after the 2 9 8 inoculation of AAV5 carrying human β -syn under the control of chicken beta-actin promoter 2 9 9
including a CMV enhancer element (CBA) in the substantia nigra of rats 11 . Before this study, the transgene in the cerebral region injected, there is an important variability of the expression it was suggested to depend on a specific α -syn/β-syn ratio in cell culture 10 .
3 1 3
The present study suggest for the first time that β -syn overexpression could not be benefic in a However, even though we could not detect any protective effects of β-syn, our study confirms
that an AAV vector is suitable for long-term overexpression of proteins into the CNS. Notably, after ICV inoculations of AAV in neonates, we confirmed a widespread expression 3 2 2 of the protein, as this was also recently described using an α-syn AAV vector 30 . The injection suggested in a previous study using serotype 9 AAV vector carrying a lysosomal enzyme which can be used for the assessment of future therapeutic strategies. human gene of β -syn or eGFP under control of the neuron-specific synapsin 1 gene promoter 3 5 0 ( Figure 1A ) (ii) a helper plasmid pXX6 32 and (iii) a plasmid carrying rep2 and cap9 genes 33 .
3 5 1
Vector particles were extracted and purified on an iodixanol step gradient. Titers were Inoculations: AAV vectors were injected at birth or at adulthood (two months of age), at 3 5 6 different sites of inoculation. Neonates were inoculated using 5 µL Hamilton syringe, with AAVβ-syn or 1.09*10 8 vg of AAVGFP (or with high dose: 1.5*10 9 vg of AAVβ-syn or month after the inoculation of the viral solution in adults, M83 mice were inoculated with 3 6 4 brain homogenates from a second passage of a sick M83 brain sample in M83 mice 3 6 5
(M83/M83 inoculum) or a second passage of a patient with multiple system atrophy (MSA) 3 6 6 brain sample in M83 mice (MSA/M83 inoculum) (same sample used in a previous publication 3 6 7 5 ). These homogenates were injected in the left striatum, using stereotaxic coordinates (AP:
+0.14 ML: +2 DV: -2.75). Before each stereotaxic surgery (AAV or brain extract 3 6 9 inoculation), mice have been anesthetized with a xylazine (10 mg/kg) and ketamine (100
qRT-PCR: B6C3H brains were dissected and RNA was extracted from brain regions using for the WPRE region of viral mRNA, and primers specific for GAPDH mRNA. We used the Coquette, France).
3 8 9
As already described for α -syn P detection 3,5 , plates were saturated with Superblock T20 3 9 0 (Thermo Scientific, Rockford, IL, USA) for 1 h at 25°C, under agitation (150 rpm). After 5 3 9 1 washes in PBST, 10 µg of protein (for α -syn P detection) diluted in PBST were incubated for 2 3 9 2 h at 25°C, under agitation (150 rpm). α-syn P was detected with a rabbit polyclonal antibody USA) was added at 1:2,000 (for α -syn P detection). After washing, 100 μ L of 3,3′,5,5′- Rad) which allowed to quantify the intensity of the bands. mounting. first specific M83 symptoms and euthanasia of the mouse. We right-censored mice found using Wilcoxon test, when at least one group of mice was composed of less than 6 animals. The difference was significant when p<0,05 (*), p<0,01(**), p<0,001(***) . We are grateful to Eric Morignat and Habiba Tlili for their help and advices on statistical and 4 6 8
immunofluorescence assays, respectively. We also are grateful for Olivier Biondi for its help setting up behavioral test and the method for quantifying motor neurons in the spinal cord. We thank Ronald Melki and its team for providing us preformed fibrils of recombinant α -syn. authors read and approved the final manuscript. The authors declare that they have no competing interests. I  n  t  r  a  m  u  s  c  u  l  a  r  i  n  j  e  c  t  i  o  n  o  f  a  l  p  h  a  -s  y  n  u  c  l  e  i  n  i  n  d  u  c  e  s  C  N  S  a  l  p  h  a  -s  y  n  u  c  l  e  i  n  5  3  6   p  a  t  h  o  l  o  g  y  a  n  d  a  r  a  p  i  d  -o  n  s  e  t  m  o  t  o  r  p  h  e  n  o  t  y  p  e  i  n  t  r  a  n  s  g  e  n  i  c  m  i  c  e  .  P  r  o  c  e  e  d  i  n  g  s  o  f  t  h  e  5  3  7   N  a  t  i  o  n  a  l  A  c  a  d  e  m  y  o  f  S  c  i  e  n  c  e  s  o  f  t  h  e  U  n  i  t  e  d  S  t  a  t  e  s  o  f  A  m  e  r  i  c  a   1  1  1   ,  1  0  7  3  2  -1  0  7  3  7  ,  5  3  8   d  o  i  :  1  0  .  1  0  7  3  /  p  n  a  s  .  1  3  2  1  7  8  5  1  1  1  (  2  0  1  4  )  .  5  3  9   1  8  A  r  m  b  r  u  s  t  e  r  ,  N  .  e  t  a  l  .  E  f  f  i  c  a  c  y  a  n  d  b  i  o  d  i  s  t  r  i  b  u  t  i  o  n  a  n  a  l  y  s  i  s  o  f  i  n  t  r  a  c  e  r  e  b  r  o  v  e  n  t  r  i  c  u  l  a  r  5  4 
